期刊
JOURNAL OF TRANSLATIONAL MEDICINE
卷 20, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12967-022-03365-z
关键词
-
资金
- Novo Nordisk Foundation [NNF20CC0035580, NNF14OC0009473]
- Engineering and Physical Sciences Research Council (EPSRC) [EP/S001301/1]
- Biotechnology Biological Sciences Research Council (BBSRC) [BB/S016899/1]
- Science for Life Laboratory
- BBSRC [BB/S016899/1] Funding Source: UKRI
This article summarizes the research progress on the microbiome in irritable bowel syndrome (IBS), pointing out the lack of established microbial mechanisms and clear treatment methods for IBS. The review proposes a new treatment perspective, using data-driven approach and computational modeling to design microbiome-aware personalized treatment strategies.
The human microbiome has been linked to several diseases. Gastrointestinal diseases are still one of the most prominent area of study in host-microbiome interactions however the underlying microbial mechanisms in these disorders are not fully established. Irritable bowel syndrome (IBS) remains as one of the prominent disorders with significant changes in the gut microbiome composition and without definitive treatment. IBS has a severe impact on socio-economic and patient's lifestyle. The association studies between the IBS and microbiome have shed a light on relevance of microbial composition, and hence microbiome-based trials were designed. However, there are no clear evidence of potential treatment for IBS. This review summarizes the epidemiology and socioeconomic impact of IBS and then focus on microbiome observational and clinical trials. At the end, we propose a new perspective on using data-driven approach and applying computational modelling and machine learning to design microbiome-aware personalized treatment for IBS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据